{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:38:02Z","timestamp":1769611082252,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40272-025-00717-2","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:48:07Z","timestamp":1759927687000},"page":"761-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-645X","authenticated-orcid":false,"given":"Serena Yun-Chen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harland S.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"717_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2468-1253(24)00319-4","volume":"10","author":"O Atia","year":"2025","unstructured":"Atia O, Shavit-Brunschwig Z, Lev-Tzion R, Stein R, Broide E, Urlep D, et al. Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study. Lancet Gastroenterol Hepatol. 2025;10:234\u201347. https:\/\/doi.org\/10.1016\/S2468-1253(24)00319-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"717_CR2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","volume":"17","author":"J Meserve","year":"2019","unstructured":"Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1533-1540.e2. https:\/\/doi.org\/10.1016\/j.cgh.2018.09.035.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"717_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40272-023-00586-7","volume":"25","author":"S Fang","year":"2023","unstructured":"Fang S, Zhang S, Zhang C, Wang L. Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: a systematic review. Paediatr Drugs. 2023;25:499\u2013513. https:\/\/doi.org\/10.1007\/s40272-023-00586-7.","journal-title":"Paediatr Drugs"},{"key":"717_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/MIB.0000000000000865","volume":"22","author":"N Singh","year":"2016","unstructured":"Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:2121\u20136. https:\/\/doi.org\/10.1097\/MIB.0000000000000865.","journal-title":"Inflamm Bowel Dis"},{"key":"717_CR5","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1111\/j.1572-0241.2008.01960.x","volume":"103","author":"LJ Herrinton","year":"2008","unstructured":"Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996\u20132002. Am J Gastroenterol. 2008;103:1998\u20132006. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.01960.x.","journal-title":"Am J Gastroenterol"},{"key":"717_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf042","volume":"19","author":"T Chhibba","year":"2025","unstructured":"Chhibba T, Gros B, King JA, Windsor JW, Gorospe J, Leibovitzh H, et al. Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health. J Crohns Colitis. 2025;19:jjaf042. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf042.","journal-title":"J Crohns Colitis"},{"key":"717_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/ecco-jcc\/jjab205","volume":"16","author":"O Atia","year":"2022","unstructured":"Atia O, Harel S, Ledderman N, Greenfeld S, Kariv R, Dotan I, et al. Risk of cancer in paediatric onset inflammatory bowel diseases: a nation-wide study from the epi-IIRN. J Crohns Colitis. 2022;16:786\u201395. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab205.","journal-title":"J Crohns Colitis"},{"key":"717_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","volume":"4","author":"M Argollo","year":"2019","unstructured":"Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J-F, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019;4:643\u201354. https:\/\/doi.org\/10.1016\/S2468-1253(19)30173-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"717_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ajg.2011.63","volume":"106","author":"AJ Yarur","year":"2011","unstructured":"Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741. https:\/\/doi.org\/10.1038\/ajg.2011.63.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"717_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","volume":"26","author":"K Cheng","year":"2020","unstructured":"Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020;26(12):1231\u201341. https:\/\/doi.org\/10.3748\/wjg.v26.i12.1231.","journal-title":"World J Gastroenterol"},{"issue":"40","key":"717_CR11","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.3748\/wjg.v27.i40.6757","volume":"27","author":"A Stadnicki","year":"2021","unstructured":"Stadnicki A, Stadnicka I. Venous and arterial thromboembolism in patients with inflammatory bowel diseases. World J Gastroenterol. 2021;27(40):6757\u201374. https:\/\/doi.org\/10.3748\/wjg.v27.i40.6757.","journal-title":"World J Gastroenterol"},{"key":"717_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5009\/gnl210190","volume":"16","author":"SY Kim","year":"2022","unstructured":"Kim SY, Cho YS, Kim H-S, Lee JK, Kim HM, Park HJ, et al. Venous thromboembolism risk in Asian patients with inflammatory bowel disease: a population-based nationwide inception cohort study. Gut Liver. 2022;16:555\u201366. https:\/\/doi.org\/10.5009\/gnl210190.","journal-title":"Gut Liver"},{"key":"717_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2352-4642(24)00078-6","volume":"8","author":"RCW Klomberg","year":"2024","unstructured":"Klomberg RCW, Hellendoorn AE, Kemos P, Rizopoulos D, Ruemmele FM, Croft NM, et al. Rare and severe adverse events in children with inflammatory bowel disease: analysis of data from the PIBD-SETquality safety registry. Lancet Child Adolesc Health. 2024;8:422\u201332. https:\/\/doi.org\/10.1016\/S2352-4642(24)00078-6.","journal-title":"Lancet Child Adolesc Health"},{"key":"717_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae249","author":"PR Harvey","year":"2024","unstructured":"Harvey PR, McNulty D, Coupland B, Kemos P, Croft NM, Trudgill NJ. The risk of venous thromboembolism in children with inflammatory bowel disease. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae249.","journal-title":"Inflamm Bowel Dis"},{"key":"717_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/ecco-jcc\/jjx162","volume":"12","author":"P Sarlos","year":"2018","unstructured":"Sarlos P, Szemes K, Hegyi P, Garami A, Szabo I, Illes A, et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis. J Crohns Colitis. 2018;12:489\u201398. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx162.","journal-title":"J Crohns Colitis"},{"key":"717_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cgh.2014.07.017","volume":"13","author":"PDR Higgins","year":"2015","unstructured":"Higgins PDR, Skup M, Mulani PM, Lin J, Chao J. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:316\u201321. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.017.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"717_CR17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.14309\/ajg.0000000000002676","volume":"119","author":"G Dragoni","year":"2024","unstructured":"Dragoni G, Innocenti T, Amiot A, Castiglione F, Melotti L, Festa S, et al. Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study. Am J Gastroenterol. 2024;119:1525\u201335. https:\/\/doi.org\/10.14309\/ajg.0000000000002676.","journal-title":"Am J Gastroenterol"},{"key":"717_CR18","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328:2446\u20137. https:\/\/doi.org\/10.1001\/jama.2022.21383.","journal-title":"JAMA"},{"key":"717_CR19","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMp2407586","volume":"391","author":"RA Hubbard","year":"2024","unstructured":"Hubbard RA, Gatsonis CA, Hogan JW, Hunter DJ, Normand S-LT, Troxel AB. \u201cTarget trial emulation\u201d for observational studies\u2014potential and pitfalls. N Engl J Med. 2024;391:1975\u20137. https:\/\/doi.org\/10.1056\/NEJMp2407586.","journal-title":"N Engl J Med"},{"key":"717_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/ibd\/izae131","volume":"31","author":"S Honap","year":"2024","unstructured":"Honap S, Danese S, Peyrin-Biroulet L. Target trial emulation: improving the quality of observational studies in inflammatory bowel disease using the principles of randomized trials. Inflamm Bowel Dis. 2024;31:843\u20139. https:\/\/doi.org\/10.1093\/ibd\/izae131.","journal-title":"Inflamm Bowel Dis"},{"key":"717_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8:11. https:\/\/doi.org\/10.1038\/s41572-022-00336-y.","journal-title":"Nat Rev Dis Primers"},{"key":"717_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/jth.13349","volume":"14","author":"EFW van Vlijmen","year":"2016","unstructured":"van Vlijmen EFW, Wiewel-Verschueren S, Monster TBM, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2016;14:1393\u2013403. https:\/\/doi.org\/10.1111\/jth.13349.","journal-title":"J Thromb Haemost"},{"key":"717_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"key":"717_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225572","volume":"14","author":"RK Cross","year":"2019","unstructured":"Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, et al. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS ONE. 2019;14:e0225572. https:\/\/doi.org\/10.1371\/journal.pone.0225572.","journal-title":"PLoS ONE"},{"key":"717_CR25","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1016\/S0016-5085(17)32086-3","volume":"152","author":"RK Cross","year":"2017","unstructured":"Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, et al. The Incidence of cardiovascular events in patients with Crohn\u2019s disease treated with vedolizumab and anti-TNF therapies. Gastroenterology. 2017;152:S577\u20138. https:\/\/doi.org\/10.1016\/S0016-5085(17)32086-3.","journal-title":"Gastroenterology"},{"key":"717_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","volume":"18","author":"PA Olivera","year":"2021","unstructured":"Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:857\u201373. https:\/\/doi.org\/10.1038\/s41575-021-00492-8.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"717_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/MCG.0000000000000408","volume":"50","author":"AM deFonseka","year":"2016","unstructured":"deFonseka AM, Tuskey A, Conaway MR, Behm BW. Antitumor necrosis factor-\u03b1 therapy is associated with reduced risk of thromboembolic events in hospitalized patients with inflammatory bowel disease. J Clin Gastroenterol. 2016;50:578\u201383. https:\/\/doi.org\/10.1097\/MCG.0000000000000408.","journal-title":"J Clin Gastroenterol"},{"key":"717_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/MCG.0000000000001290","volume":"54","author":"I Detrez","year":"2020","unstructured":"Detrez I, Thomas D, Van Steen K, Ballet V, Peeters M, Hoylaerts MF, et al. Successful infliximab treatment is associated with reversal of clotting abnormalities in inflammatory bowel disease patients. J Clin Gastroenterol. 2020;54:819. https:\/\/doi.org\/10.1097\/MCG.0000000000001290.","journal-title":"J Clin Gastroenterol"},{"key":"717_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/JIR.S500600","volume":"18","author":"K Su","year":"2025","unstructured":"Su K, Xiao S, Wang M, Wang K, Fan Q, Sha S, et al. Predictive value of albumin to fibrinogen ratio and CALLY index for diagnosis of ulcerative colitis and mucosal healing after vedolizumab treatment. J Inflamm Res. 2025;18:589\u2013600. https:\/\/doi.org\/10.2147\/JIR.S500600.","journal-title":"J Inflamm Res"},{"key":"717_CR30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11938-020-00304-z","volume":"18","author":"T Lambin","year":"2020","unstructured":"Lambin T, Faye AS, Colombel J-F. Inflammatory bowel disease therapy and venous thromboembolism. Curr Treat Options Gastroenterol. 2020;18:462\u201375. https:\/\/doi.org\/10.1007\/s11938-020-00304-z.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"717_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14712598.2020.1707800","volume":"20","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Maida M, Ventimiglia M, Cottone M, Orlando A. Effectiveness and safety of ustekinumab for the treatment of Crohn\u2019s disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther. 2020;20:193\u2013203. https:\/\/doi.org\/10.1080\/14712598.2020.1707800.","journal-title":"Expert Opin Biol Ther"},{"key":"717_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","volume":"13","author":"C Liefferinckx","year":"2019","unstructured":"Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13:1401\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz080.","journal-title":"J Crohns Colitis"},{"key":"717_CR33","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/s41598-018-20220-8","volume":"8","author":"MJ Page","year":"2018","unstructured":"Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF-\u03b1 and complement component 3 on coagulation. Sci Rep. 2018;8:1812. https:\/\/doi.org\/10.1038\/s41598-018-20220-8.","journal-title":"Sci Rep"},{"key":"717_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","volume":"118","author":"JH Foley","year":"2016","unstructured":"Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118:1392\u2013408. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306853.","journal-title":"Circ Res"},{"key":"717_CR35","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1172\/JCI19284","volume":"112","author":"B Cambien","year":"2003","unstructured":"Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-\u03b1. J Clin Invest. 2003;112:1589\u201396. https:\/\/doi.org\/10.1172\/JCI19284.","journal-title":"J Clin Invest"},{"key":"717_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf078","author":"M Gozdzik","year":"2025","unstructured":"Gozdzik M, Unninayar D, Siegal DM, Sarker AK, Kim E, Murthy S, et al. Risk factors for venous thromboembolism in inflammatory bowel disease: a systematic review and meta-analysis by phase of care. Inflamm Bowel Dis. 2025. https:\/\/doi.org\/10.1093\/ibd\/izaf078.","journal-title":"Inflamm Bowel Dis"},{"key":"717_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11605-022-05525-4","volume":"27","author":"AS Ore","year":"2023","unstructured":"Ore AS, Vigna C, Fabrizio A, Cataldo TE, Messaris E, Crowell K. Are IBD patients underscored when determining postoperative VTE risk? J Gastrointest Surg. 2023;27:347\u201353. https:\/\/doi.org\/10.1007\/s11605-022-05525-4.","journal-title":"J Gastrointest Surg"},{"key":"717_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14712598.2023.2185510","volume":"23","author":"G Mocci","year":"2023","unstructured":"Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, et al. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn\u2019s disease: results from an Italian multicenter study. Expert Opin Biol Ther. 2023;23:293\u2013304. https:\/\/doi.org\/10.1080\/14712598.2023.2185510.","journal-title":"Expert Opin Biol Ther"},{"key":"717_CR39","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/ecco-jcc\/jjac036","volume":"16","author":"JS Hyams","year":"2022","unstructured":"Hyams JS, Turner D, Cohen SA, Szakos E, Kowalska-Duplaga K, Ruemmele F, et al. Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or crohn\u2019s disease: results from the phase 2 HUBBLE study. J Crohns Colitis. 2022;16:1243\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac036.","journal-title":"J Crohns Colitis"},{"key":"717_CR40","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/apt.18006","volume":"59","author":"TH Yiu","year":"2024","unstructured":"Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta-analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59:1312\u201334. https:\/\/doi.org\/10.1111\/apt.18006.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00717-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00717-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00717-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:29:12Z","timestamp":1760714952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00717-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00717-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.N.A.: consultant: Geneoscopy. H.S.W.: consultant: Abbvie, Janssen Pharmaceuticals, Pfizer, and Phathom Pharmaceuticals; research support: Janssen Pharmaceuticals, Nestle, Women\u2019s Wellness Foundation, Autism Research Institute, Scipher Pharmaceuticals, Abbvie, and Pediatric IBD Foundation. S.Y.T. and K.S.M.: none reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data are available on request by contacting the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The study was exempt from institutional review board approval and informed consent requirements owing to the use of deidentified data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"S.Y.T., K.S.M., and H.S.W. designed the model and the computational framework; S.Y.T. and K.S.M. analyzed the data; S.Y.T. took the lead in writing the manuscript in consultation with A.N.A., H.S.W., and K.S.M. All authors provided critical feedback and helped shape the research, analysis, and manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}